KETINK 100 MG/ML SOLUTION FOR INJECTION FOR CATTLE, HORSES AND PIGS

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
09-05-2017

Aktīvā sastāvdaļa:

KETOPROFEN

Pieejams no:

Industrial Veterinaria, S.A.

ATĶ kods:

QM01AE03

SNN (starptautisko nepatentēto nosaukumu):

KETOPROFEN

Deva:

100 Mg/Ml

Zāļu forma:

Solution for Injection

Receptes veids:

POM

Ārstniecības grupa:

Bovine, Equine - Food, Porcine

Ārstniecības joma:

Ketoprofen

Ārstēšanas norādes:

N.S.A.I.D

Autorizācija statuss:

Authorised

Autorizācija datums:

2012-02-10

Produkta apraksts

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ketink 100 mg/ml solution for injection for cattle, horses and pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Ketoprofen 100 mg
EXCIPIENTS:
Benzyl alcohol (E1519) 10 mg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear, colourless to yellow solution. Free from visible particles.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, pigs and horses.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_Cattle:_ Anti-inflammatory and analgesic treatment of diseases in the
musculoskeletal system and the udder.
_Pigs:_
Anti-inflammatory and antipyretic treatment
of
Postpartum Dysgalactia Syndrome -PDS-
(Metritis Mastitis
Agalactia Syndrome) and respiratory diseases.
_Horses:_ Anti-inflammatory and analgesic treatment of diseases in the
musculoskeletal system and joints.
Symptomatic analgesic treatment for colic. Postoperative pain and
swelling.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance, or to
any of the excipients.
Do not
use in animals suffering from gastro-intestinal
lesions,
haemorrhagic diathesis,
blood dyscrasia,
impaired
hepatic, cardiac or renal function.
Do not use in foals in their first month of life.
Do not use other non-steroidal anti-inflammatory drugs (NSAIDs)
concurrently or within 24 hours of each other.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_

                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu